alt text

Hugo Geerts, PhD

Chief Scientist, In Silico Biosciences

For his work at Janssen contributing to the development of Razadyne, one of only five FDA approved medications for Alzheimer's, as a treatment to slow the progression of symptoms in mild to moderate disease, and for his work at In Silico Biosciences on computer modeling to advance clinical trial design.

Hugo Geerts has almost twenty years of experience in drug discovery and development as a Research Fellow at the Janssen Research Foundation laboratory in Beerse, Belgium. At Janssen he was involved in the successful development, launch and lifecycle management of galantamine (Reminyl, Razadyne) for Alzheimer’s disease. Dr. Geerts has a bachelor’s degree in theoretical physics, a bachelor’s degree in medicine, a PhD in biophysics from the University of Antwerp, and a Pharmaceutical Executive MBA degree from Drexel’s Lebow College of Business in Philadelphia. Dr. Geerts is an Adjunct Professor in the School of Medicine at the University of Pennsylvania, he has more than sixty-five peer-reviewed publications, and he is the inventor/co-inventor on twelve patents.


Photos from the 2019 Cure Coin Award Ceremony - July 2019 - The Association, LA